Formycon AG

General information
Formycon AG
Fraunhoferstraße 15
82152 Martinsried/Planegg, Bavaria
Germany

Contact person: Stefan Glombitza, Chief Executive Officer
Company main phone: +49 (89) 864667100
Company main fax:  +49 (89) 864667110
Website:  https://www.formycon.com
Year founded:1999
Source of foundation:Independent foundation
No. of employees: Worldwide:  224
Corporate description / mission:
Formycon is a developer of biopharmaceutical medicines, especially biosimilars. The company is focused on the treatments in ophthalmology, immunology and on other key chronic diseases.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2012
Remarks on ownership / listings
In 1999, founded the Scil Group.
In 2012, changed the name to Formycon AG
Categorization
Sector:
  • Pharma (fully integrated)
Subsector:
  • Anti-infectives
  • Biosimilars
  • Immunotherapy
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:2
Phase III:2
On the market:1
Description of products:
FYB201
FYB202
FYB203
FYB207 etc.
Financing details
Fiscal year (end of) 2022
Revenues:EUR 42.50M
R&D expenses:EUR 16.91M
Net earnings:EUR 35.99M
No. of shares:16'038'800
Market cap. / valuation:EUR 877.24M
© 2023 Biotechgate by Venture Valuation
X